Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 801–900 of 1,619
Omote, N., & Sauler, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.603047 · Cited by 17
“Additionally, while fibroblast senescence is important for normal wound healing, IPF pathogenesis may involve the persistence of senescent fibroblasts that secrete pro-fibrotic mediators and senescent myofibroblasts that are apoptosis resistant (23, 31).”
BackgroundMohrin, M., Liu, J., Zavala‐Solorio, J., Bhargava, S., Trumble, J. M., Brito, A., Hu, D. Z., Brooks, D. J., Κούκος, Γ., Alabdulaaly, L., et al. (2021) · Aging Cell · doi:10.1111/acel.13313 · Cited by 21
Sullivan, D. I., Jiang, M., Hinchie, A. M., Roth, M. G., Bahudhanapati, H., Nouraie, M., Liu, J., McDyer, J. F., Mallampalli, R. K., Zhang, Y., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.600626 · Cited by 16
“Additionally, secondary mesenchymal effects were seen in vivo that were hypothesized to be due to AEC2s adopting the senescence-associated secretory phenotype (SASP) (9)—a set of characteristic, paracrine signaling pathways (31) that is believed to play a role in the progression of fibrotic lung disease (32).”
BackgroundChávez‐Galán, L., Becerril, C., Ruíz, A., Ramón‐Luing, L. A., Cisneros, J., Montaño, M., Salgado-Aguayo, A. R., Ramos, C., Buendía-Roldán, I., Pardo, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.820347 · Cited by 20
“Additionally, strong evidence indicates that fibroblasts/ myofibroblasts from IPF lungs are senescent, which are characterized by irreversible cell-cycle arrest, higher resistance to apoptosis, and secretion of a complex set of mediators, known as the senescence-associated secretory phenotype (11, 12, 23).”
BackgroundCellular Senescence and Ageing
Reed, R., & Miwa, S. (2023) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-21410-3_7 · Cited by 16
Aging-Related Mechanisms Contribute to Corticosteroid Insensitivity in Elderly Asthma
Ford, M. L., Ruwanpathirana, A., Lewis, B. W., & Britt, R. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076347 · Cited by 20
“context of lung diseases, targeting and eliminating senescent cells has been shown to reduce lung fibrosis in bleomycin-induced fibrosis in mice [54,55], suggesting senescence is a targetable pathway to alleviate lung disease.”
BackgroundBCL-2 Modulates IRE1α Activation to Attenuate Endoplasmic Reticulum Stress and Pulmonary Fibrosis
Saux, C. J. L., Ho, T. C., Brumwell, A. M., Kathiriya, J. J., Wei, Y. J., Hughes, J. B., Garakani, K., Atabai, K., Auyeung, V. C., Papa, F. R., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0109oc · Cited by 20
Elimination of Senescent Cells: Prospects According to the Subtelomere-Telomere Theory
Libertini, G., Ferrara, N., Rengo, G., & Corbi, G. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918120064 · Cited by 19
Santos, J. C., Ribeiro, M. L., & Gambero, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.612268 · Cited by 16
The Role of Herpes Viruses in Pulmonary Fibrosis
Duckworth, A., Longhurst, H. J., Paxton, J. K., & Scotton, C. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.704222 · Cited by 20
“Studies in mouse models have shown that it is the AEC2 that are key to the short telomeric cause of lung remodeling and fibrosis (98) with dysfunctional chromosomal replication leading to cellular senescence and triggering the pro-fibrotic senescence-associated secretory phenotype (SASP) (99).”
BackgroundLucas, J. H., Wang, Q., Muthumalage, T., & Rahman, I. (2021) · Toxics · doi:10.3390/toxics9060144 · Cited by 20
“Analysis of lung tissues from patients show increased levels of established senescence biomarkers such as p21, p16, and senescence associated β-galactosidase (SA β-gal) [5, 6].”
Backgroundp21 facilitates chronic lung inflammation via epithelial and endothelial cells
Levi, N., Papismadov, N., Majewska, J., Roitman, L., Wigoda, N., Eilam, R., Tsoory, M., Rotkopf, R., Ovadya, Y., Akiva, H., et al. (2023) · Aging · doi:10.18632/aging.204622 · Cited by 15
“The long-term persistence of senescent cells is deleterious and can promote the development of age-related pathologies [28, 29, 68].”
Phillips, P. C. A., Branco, M. S. L. A., Cliff, C. L., Ward, J. K., Squires, P. E., & Hills, C. E. (2024) · Diabetic Medicine · doi:10.1111/dme.15408 · Cited by 20
Martín-Vicente, P., López‐Martínez, C., López-Alonso, I., Exojo-Ramírez, S. M., Duarte-Herrera, I. D., Amado‐Rodríguez, L., Ordoñez, I., Cuesta‐Llavona, E., Gómez, J., Campo, N., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0449oc · Cited by 18
Transcriptomics of interstitial lung disease: a systematic review and meta-analysis
He, D. X., Guler, S. A., Shannon, C. P., Ryerson, C. J., & Tebbutt, S. J. (2024) · European Respiratory Journal · doi:10.1183/13993003.01070-2024 · Cited by 18
“Eight datasets were associated with the LTRC, and duplicate LTRC samples across studies were removed where LTRC identifiers were available [11, 13, 39, 42 – 44, 50, 54 – 56].”
The Intersection of Epigenetics and Senolytics in Mechanisms of Aging and Therapeutic Approaches
Burdusel, D., Doeppner, T. R., Surugiu, R., Hermann, D. M., Olaru, D. G., & Popa‐Wagner, A. (2024) · Biomolecules · doi:10.3390/biom15010018 · Cited by 18
Du, H., Rose, J., Bons, J., Guo, L., Valentino, T. R., Wu, F., Burton, J. B., Basisty, N., Manwaring-Mueller, M., Makhijani, P., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01507-x · Cited by 19
“Furthermore, in some fibrotic diseases, including pulmonary fibrosis, senescent cells, and sSASP have been found to actively exacerbate fibrosis [10].”
Meister, M. L., Sharma, S., He, X., Chepaitis, P. S., Waddey, T., Wilson, M., Premnath, V., Jeevarajan, J. A., Black, M., & Wright, C. (2025) · Environment International · doi:10.1016/j.envint.2025.109466 · Cited by 21
Tran, K. A., Gilbert, M., Vazquez, B. N., Ianni, A., Garcia, B. A., Vaquero, A., & Berger, S. L. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.05.025 · Cited by 15
SIRT3-Mediated Mitochondrial Regulation and Driver Tissues in Systemic Aging
Šešelja, K., Šimunić, E., Sobočanec, S., Podgorski, I. I., Pinterić, M., Hadžija, M. P., Balog, T., & Belužić, R. (2025) · Genes · doi:10.3390/genes16121497 · Cited by 19
“These alterations push cells toward a senescent phenotype, characterized by irreversible growth arrest and the secretion of a complex array of pro-inflammatory and pro-fibrotic mediators known as the senescence-associated secretory phenotype (SASP) [12,13].”
A model of the aged lung epithelium in idiopathic pulmonary fibrosis
Shaghaghi, H., Cuevas-Mora, K., Para, R., Tran, C., Roque, W., Robertson, M. J., Rosas, I. O., Summer, R. S., & Romero, F. (2021) · Aging · doi:10.18632/aging.203291 · Cited by 14
Deficiency in the zinc transporter ZIP8 impairs epithelia renewal and enhances lung fibrosis
Foster, P. S., Tay, H. L., & Oliver, B. G. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160595 · Cited by 16
“Accelerated cellular aging occurs in IPF and scientifically presents a stronger case for the importance of aging in disease pathogenesis than the actual age of the person (5).”
BackgroundAn update on current and emerging drug treatments for idiopathic pulmonary fibrosis
Trachalaki, A., Sultana, N., & Wells, A. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2213436 · Cited by 15
“The elimination of senescent cells in preclinical models of IPF has been shown to reduce fibrosis, improve lung function, and increase survival [171].”
BackgroundTorrance, B. L., Cadar, A. N., Martin, D. E., Panier, H. A., Lorenzo, E. C., Bartley, J. M., Xu, M., & Haynes, L. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1212750 · Cited by 21
“This combination is well suited for our studies due to its demonstrated efficacy in clearing senescent cells in the lungs of aged mice (Schafer et al., 2017).”
BackgroundLEF1 isoforms regulate cellular senescence and aging
Jia, M., Sayed, K., Kapetanaki, M. G., Dion, W. A., Rosas, L., Irfan, S., Valenzi, E., Mora, A. L., Lafyatis, R., Rojas, M. M., et al. (2023) · Aging Cell · doi:10.1111/acel.14024 · Cited by 19
“In view of the key role of cellular se - nescence in IPF (De Man et al., 2023; Schafer et al., 2017), we measured the protein levels of both LEF1 isoforms in tissue lung samples from healthy and IPF donors.”
BackgroundTherapy-induced normal tissue damage promotes breast cancer metastasis
Perkins, D. W., Steiner, I., Haider, S., Robertson, D. M., Buus, R., O’Leary, L., & Isacke, C. M. (2023) · iScience · doi:10.1016/j.isci.2023.108503 · Cited by 21
“underpin a range of age-related pathological conditions including idiopathic pulmonary fibrosis, atherosclerosis, osteoarthritis and renal failure (Baker et al., 2016; Baker et al., 2011; Schafer et al., 2017).”
BackgroundIjima, S., Saito, Y., Yamamoto, S., Nagaoka, K., Iwamoto, T., Kita, A., Miyajima, M., Sato, T., Miyazaki, A., & Chikenji, T. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00400-5 · Cited by 17
de Godoy, M. C. X., Macedo, J. A., & Gambero, A. (2024) · Pharmaceuticals · doi:10.3390/ph17010070 · Cited by 18
“Therapies that target cellular senescence, including senolytic and senomorphic drugs, stem cell therapies, redox control, and other interventions, have been shown to reduce tissue injury in animal models of lung disease [9,17,18].”
BackgroundEmerging role of cellular senescence in normal lung development and perinatal lung injury
Dennery, P. A., & Yao, H. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.01.001 · Cited by 20
T-cell immunity against senescence: potential role and perspectives
Matveeva, K. S., Vasilieva, M., Minskaia, E., Александрович, Р. С., & Shevyrev, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360109 · Cited by 18
Laliberté, C., Bossé, B., Bourdeau, V., Prieto, L. I., Perron-Deshaies, G., Vuong, N., Igelmann, S., Aguilar, L. C., Oeffinger, M., Baker, D. J., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051089 · Cited by 22
“Senescent cells accumulate in aging organisms [8–11] and are linked to age-related diseases, such as pulmonary fibrosis [12,13], type 2 diabetes, [14] and osteoarthritis [15–17].”
BackgroundThe Lung in Rheumatoid Arthritis—Friend or Enemy?
Anton, M.-L., Cardoneanu, A., Burlui, A., Mihai, I. R., Richter, P., Bratoiu, I., Macovei, L. A., & Rezuş, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126460 · Cited by 17
“The senescence of lung parenchyma cellularity plays a key role in pulmonary damage by activating FMT [141,142].”
BackgroundEndometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01740-5 · Cited by 21
“…aging-related changes, which occur heterogeneously in different organ systems, as a risk factor for eventual organ dysfunction in a number of age-related diseases such as cardiovascular disease [47, 48], cancers [48–50], type 2 diabetes [51–53], and idiopathic interstitial pneumonia [54, 55].”
BackgroundSacchi, M., Tomaselli, D., Ruggeri, M. L., Aiello, F. B., Sabella, P., Dore, S., Pinna, A., Mastropasqua, R., Nubile, M., & Agnifili, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052327 · Cited by 25
Detrimental pro-senescence effects of vitamin D on lung fibrosis
Guijarro, T., Magro-López, E., Manso, J., Martínez, R. G., Fernández‐Aceñero, M. J., Liste, I., & Zambrano, A. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0064-z · Cited by 16
“…in this article, unless otherwise stated. senescence biomarkers accumulate in both fibroblasts and epithelial cells in IPF lungs including the expression of CDKN1A (p21), CDKN2A (p16), senescenceassociated β-galactosidase activity (SA-βgal) and DNA damage (Kuwano et al. 1996; Schafer et al. 2017).”
BackgroundBlagosklonny, M. V. (2018) · Aging · doi:10.18632/aging.101750 · Cited by 17
“Nevertheless, targeting senescent cells has been shown in animal models to prevent such age-related pathologies as emphysema [12], lung fibrosis [13-15], atherosclerosis [16, 17], osteoporosis [18], osteoarthritis [19-20], renal disease [21], intervertebral disk pathology [2], hepatic steatosis [22] and other age-rela…”
BackgroundCellular Senescence in Renal and Urinary Tract Disorders
Santin, Y., Lluel, P., Rischmann, P., Gamé, X., Mialet‐Perez, J., & Parini, A. (2020) · Cells · doi:10.3390/cells9112420 · Cited by 17
Bale, L. K., Schafer, M. J., Atkinson, E. J., LeBrasseur, N. K., Haak, A. J., Oxvig, C., & Conover, C. A. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30687 · Cited by 17
Self-citationLiu, Y., Schwam, J., & Chen, Q. (2022) · Cells · doi:10.3390/cells11071089 · Cited by 20
Pentoxifylline Inhibits Pulmonary Fibrosis by Regulating Cellular Senescence in Mice
Lin, Y., Xu, Z., Zhou, B., Ma, K., & Jiang, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.848263 · Cited by 20
“Previous studies have raised concerns about the shortcomings of BLM animal models of IPF (Schafer et al., 2017).”
BackgroundResultZuo, B., Zuo, L., Du, X., Yuan, S., Xuan, C., Zhang, Y., Chen, Z., & Cao, W.-F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1033919 · Cited by 17
“Cellular senescence is thought to be a major driver of the malignant progression of PF (Schafer et al., 2017).”
BackgroundRecent Advances in Senolysis for Age-Related Diseases
Aratani, S., & Nakanishi, M. (2023) · Physiology · doi:10.1152/physiol.00003.2023 · Cited by 19
Hong, J., Jin, L., Zhang, C.-Y., Zhong, W., Yang, H., Wang, G.-M., Ma, S., Guan, C., Li, Q., & Zhou, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17361 · Cited by 14
“In mice, removing senescent cells using senolytics, such as dasatinib and quercetin, has been shown to attenuate bleomycin-induced PF [8].”
BackgroundSenescence in the lung: is this getting old?
Morty, R. E., & Prakash, Y. S. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00081.2019 · Cited by 17
Self-citationAnalysis of the senescence‐associated cell surfaceome reveals potential senotherapeutic targets
Deng, Y., Liu, T., Scifo, E., Li, T., Xie, K., Taschler, B., Morsy, S., Schaaf, K., Ehninger, A., Bano, D., et al. (2024) · Aging Cell · doi:10.1111/acel.14312 · Cited by 16
Li, G., Zhang, Y., Jiang, H., Wu, X., Hao, Y., Su, Y., Zou, Y., Xian, W., Wang, F., & Du, Q. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41628 · Cited by 23
Update of Aging Hallmarks in Idiopathic Pulmonary Fibrosis
Torres‐Machorro, A. L., García-Vicente, Á., Espina-Ordoñez, M., Luis‐García, E. R., Negreros, M., Herrera, I., Becerril, C., Toscano-Marquez, F., Cisneros, J., & Maldonado, M. (2025) · Cells · doi:10.3390/cells14030222 · Cited by 19
“Experiments using senolytic therapies to eliminate senescent cells have shown promising results in the murine fibrosis model, decreasing fibrotic markers and increasing pulmonary functions [120,178,179,187].”
Dasatinib and Quercetin Mitigate Age‐Related Alveolar Bone Inflammaging and Neutrophil Infiltration
Tang, J., Li, J., Hou, Z., He, R., Li, B., Gong, J., Xie, Y., Meng, W., Liu, Y., Ouchi, T., et al. (2025) · Oral Diseases · doi:10.1111/odi.15291 · Cited by 18
“…including osteoporosis, insulin resistance, Alzheimer's disease, intestinal disease, kidney disease, fibrotic pulmonary disease, and TMJ degeneration (Schafer et al. 2017; Martins-Perles et al. 2020; Saccon et al. 2021; Zhou et al. 2021b; Wang et al. 2023; Farr et al. 2024; Guo, Wen et al. 2024).”
Senotherapy for chronic lung disease
Barnes, P. J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100069 · Cited by 18
Fibroblasts as regulators of lung immunity, repair and fibrosis
Bell, P. T., & Belz, G. T. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01268-4 · Cited by 21
“Myofibroblasts also upregulate senescence programmes that result in cell cycle arrest, upregulation of intrinsic prosurvival pathways and expression of a profibrotic secretome (SASP) 33,206,207 .”
Dasatinib inhibits peripapillary scleral myofibroblast differentiation
Chow, A. L., McCrea, L. T., Kimball, E., et al. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.107999 · Cited by 14
Induction of senescence upon loss of the Ash2l core subunit of H3K4 methyltransferase complexes
Bochyńska, A., Stenzel, A. T., Sayadi-Boroujeni, R., Kuo, C., Barsoum, M., Liang, W., Bussmann, P., Costa, I. G., Lüscher‐Firzlaff, J., & Lüscher, B. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac591 · Cited by 15
“Primary MEFs (pMEFs), were immortalized using an siRNA expression construct that targets the p19ARF mRNA (iMEFs) 23, 24.”
BackgroundInfluentialShyu, Y., Liao, P.-C., Huang, T., Yang, C., Lu, M., Huang, S., Lin, X., Liou, C., Kao, Y.-J., Lu, C.-H., et al. (2022) · Advanced Science · doi:10.1002/advs.202201409 · Cited by 13
Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis
Zhong, H., Zhou, Y., Mei, S., Tang, R. N., Feng, J., He, Z.-Y., Xu, Q., & Xing, S. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.967829 · Cited by 16
Deryabin, P. I., Shatrova, A. N., & Borodkina, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214251 · Cited by 16
Cellular Senescence and Frailty in Transplantation
Lorenz, E. C., Hickson, L. J., Khairallah, P., Najafi, B., & Kennedy, C. C. (2023) · Current Transplantation Reports · doi:10.1007/s40472-023-00393-6 · Cited by 14
A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect
Sato, S., Koyama, K., Ogawa, H., Murakami, K., Imakura, T., Yamashita, Y., Kagawa, K., Kawano, H., Hara, E., & Nishioka, Y. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.08.003 · Cited by 16
Wei, Y., Gao, S., Li, C., Huang, X., Xie, B., Geng, J., Dai, H., & Wang, C. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.04.008 · Cited by 17
Fujita, M., Sasada, M., Iyoda, T., & Fukai, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126591 · Cited by 15
The multifunctional protein CCN1/CYR61: Bridging physiology and disease
Kerek, R., Awad, J. S., Bassam, M., Hajjar, C., Ghantous, F., Rizk, K., & Rima, M. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.104969 · Cited by 14
[Retracted] Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
Kou, L., Kou, P., Luo, G., & Wei, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6197219 · Cited by 15
“found that the senescent fibroblasts secreted a large amount of SASP, including TGF-β, interleukin-6 (IL-6), and MMP12, which regulated pulmonary fibrosis, and deletion of senescent cells reduces pulmonary expression of these factors [108].”
BackgroundRetractedKuehnemann, C., Hu, K., Butera, K., Patel, S. K., Bons, J., Schilling, B., Aguayo‐Mazzucato, C., & Wiley, C. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.935106 · Cited by 20
“Both the SASP and eNAMPT promote some of the same diseases, including diabetes (8, 10, 12, 34, 35) and pulmonary fibrosis (9, 11, 15, 33), so it is appealing to consider senescent cells as a source of eNAMPT in these diseases.”
BackgroundGiovos, G., Yavropoulou, M. P., & Yovos, J. G. (2019) · HORMONES · doi:10.1007/s42000-019-00132-6 · Cited by 17
p19Arf Exacerbates Cigarette Smoke-Induced Pulmonary Dysfunction
Mikawa, R., Sato, T., Suzuki, Y., Baskoro, H., Kawaguchi, K., & Sugimoto, M. (2020) · Biomolecules · doi:10.3390/biom10030462 · Cited by 15
“Cellular senescence is also involved in lung disease, and bleomycin-induced idiopathic pulmonary fibrosis (IPF) was shown to be alleviated by the elimination of senescent cells in INK-ATTAC mice or the administration of the senolytic drugs dasatinib and quercetin [16]; however, the efficacy of these drugs in human IPF…”
BackgroundSenescent Cells in IPF: Locked in Repair?
Meiners, S., & Lehmann, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.606330 · Cited by 16
“Activation of senescence was confirmed in several mouse models of lung injury and fibrosis (27, 34, 37).”
BackgroundMAPKs in the early steps of senescence implemEMTation
Anerillas, C., Altés, G., & Gorospe, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1083401 · Cited by 13
“The fact that senescent cells produce pro-EMT proteins suggests that they may contribute to fibrosis in detrimental scenarios (Schafer et al., 2017; Levi et al., 2020; Ritschka et al., 2020; Anerillas et al., 2022a).”
BackgroundSingle-cell and spatial detection of senescent cells using DeepScence
Qu, Y., Ji, B., Dong, R., Gu, L., Chan, C., Xie, J., Glass, C., Wang, X.-F., Nixon, A. B., & Ji, Z. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.101035 · Cited by 30
Liu, Z., Zheng, Q., Li, Z., Huang, M., Zhong, C., Yu, R., Jiang, R., Dai, H., Zhang, J., Gu, X., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2024.105538 · Cited by 18
Use quercetin for pulmonary fibrosis: a preclinical systematic review and meta-analysis
Wu, X., Xiao, X., Su, Y., Zhang, Y., Li, G., Wang, F., Du, Q., & Yang, H. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01678-1 · Cited by 15
“In PF, lung fibroblasts and epithelial cells show a senescent phenotype and release pro-fibrotic factors (Schafer et al. 2017).”
Wu, J., Wei, Y., Peng, Q., Zhu, J. F., Shi, H., Zhao, T., & Yuan, T. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01759-3 · Cited by 16
Bi, W., Wang, R., Hou, S., Liu, W., Zhang, H., Xu, Z., Deng, J., Wang, Z., Zeng, L., & Jiang, J. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf050 · Cited by 20
Single‐Cell Insights Into Macrophage Subtypes in Pulmonary Infections
Lin, Z., Zheng, Y., Zhong, Y., & Wang, H. (2026) · Advanced Science · doi:10.1002/advs.202510758 · Cited by 13
Zhu, Y., Zhang, Y., Zhang, Q., Song, P., Zhang, J., Ma, A., Wang, C., Gao, P., Yang, T., Zhou, L., et al. (2025) · Exploration · doi:10.1002/exp.20240069 · Cited by 19
Self-citationMechanisms of fibrotic tissue remodelling: insights from systemic sclerosis
Distler, J. H. W., Launay, D., Feghali‐Bostwick, C. A., Matei, A.-E., Trojanowska, M., & Gudjonsson, J. E. (2026) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01349-z · Cited by 21
Gao, A. Y., Espinosa, A. M. D., Gianì, F., Pham, T. X., Carver, C. M., Aravamudhan, A., Bartman, C. M., Ligresti, G., Caporarello, N., Schafer, M. J., et al. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00023.2022 · Cited by 18
Self-citationFujita, Y., Fujimoto, S., Miyamoto, A., Kaneko, R., Kadota, T., Watanabe, N., Kizawa, R., Kawamoto, H., Watanabe, J. A., Utsumi, H., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0253oc · Cited by 22
Cellular Senescence in Liver Cancer: How Dying Cells Become “Zombie” Enemies
Gazzillo, A., Volponi, C., Soldani, C., Polidoro, M. A., Franceschini, B., Lleò, A., Bonavita, E., & Donadon, M. (2023) · Biomedicines · doi:10.3390/biomedicines12010026 · Cited by 15
Chen, N., Wan, X., Wang, M., Li, Y., Wang, X., Zeng, L., Zhou, J., Zhang, Y., Cheng, S., & Shen, Y. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.123625 · Cited by 13
Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK inhibitors
Kang, K. W., Choi, Y. J., Kim, M. J., Lee, Y. J., Choi, M., Shim, W. S., Park, M., & Kim, Y.-C. (2024) · Theranostics · doi:10.7150/thno.100970 · Cited by 20
Goobie, G. C., Marinescu, D.-C., Adegunsoye, A., Bourbeau, J., Carlsten, C., Clifford, R. L., Doiron, D., Duan, Q., Gibson, K. F., Grant-Orser, A., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.01618-2024 · Cited by 15
Zhang, Y., Qi, C., Wei, Q., Li, Y., & Tian, P. (2025) · Respiratory Research · doi:10.1186/s12931-025-03294-7 · Cited by 17
“Senescence is considered a key pathogenic mechanism in the development of IPF, with increased cellular senescence being one of the main hallmarks of senescence [69, 70].”
Chuang, H.-M., Ho, L.-I., Huang, M., Huang, K.-L., Chiou, T., Lin, S., Su, H.-L., & Harn, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103024 · Cited by 15
“Penh is used as an empirical index of airway resistance [26], and the result suggests that lung stiffness decreased and airway functions improved after BP treatment.”
MethodLeveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
Kato, K., Shin, Y.-J., Palumbo, S., Papageorgiou, I., Hahn, S., Irish, J. D., Rounseville, S. P., Krafty, R. T., Wollin, L., Sauler, M., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00759-2021 · Cited by 12
“Numerous studies have demonstrated the presence of premature ageing hallmarks, including the accumulation of senescent cells, in the lungs of IPF patients [4, 13].”
p16INK4a Plays Critical Role in Exacerbating Inflammaging in High Fat Diet Induced Skin
Liang, Y., Gu, T., Peng, S., Lin, Y., Liu, J., Wang, X., Huang, X., Zhang, X., Zhu, J., Zhao, L., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3415528 · Cited by 17
“The clearance of senescent cells could alleviate multiorgan liver, kidney, and lung fibrosis [23, 24].”
Conover, C. A., & Bale, L. K. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.112070 · Cited by 15
Bian, X., Snow, Z. K., Zinn, C. J., Bratulin, A. L., Elhusseiny, K. M., Tchkonia, T., Kirkland, J. L., Zhu, Y., Khosla, S., Kim, S. R., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106124 · Cited by 21
Self-citationRole of Carbon Monoxide in Oxidative Stress‐Induced Senescence in Human Bronchial Epithelium
Cai, M., Yip, C., Pan, K., Zhang, Y., Chan, R. W.-Y., Chan, W. Y., & Ko, W. H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5199572 · Cited by 11
“An accumulation of senescent airway epithelial cells has been found in the lungs of chronic lung disease patients, including COPD and idiopathic pulmonary fibrosis (IPF) [42, 43].”
Senescence in diffuse systemic sclerosis is elevated and may play a role in fibrosis
O’Reilly, S. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad077 · Cited by 14
Rao, S., Zahm, M., Casemayou, A., Buléon, M., Faguer, S., Feuillet, G., Iacovoni, J. S., Joffre, O. P., Gonzalez-Fuentes, I., Lhuillier, É., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad199 · Cited by 16
Kizawa, R., Araya, J., & Fujita, Y. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00295-1 · Cited by 15
Lettieri, S., Bertuccio, F. R., Frate, L. D., Perrotta, F., Corsico, A. G., & Stella, G. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010547 · Cited by 17
“…there is a derangement of the senescent process with the production of a repertoire of cytokines, chemokines, proteases, and extracellular matrix components by senescent fibroblasts and epithelial cells resulting in irreversible scarring, parenchymal distortion, and lung function impairment [189].”
BackgroundRoger, I., Montero, P., Milara, J., & Cortijo, J. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176547 · Cited by 18
Xie, W., Deng, L., Qian, R., Huang, X., Liu, W., & Tang, S. (2024) · Antioxidants · doi:10.3390/antiox13040420 · Cited by 13
Supramolecular Nanofibers Ameliorate Bleomycin‐Induced Pulmonary Fibrosis by Restoring Autophagy
Zheng, D., Guo, J., Liang, Z., Jin, Y., Ding, Y., Liu, J., Qi, C., Shi, K., Xie, L., Zhu, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202401327 · Cited by 21
Wang, L., Lin, F., Liu, Y., Li, W., Ding, Q., Duan, X., Yang, L., Bai, Z., Zhang, M., & Guo, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1407891 · Cited by 17
Zhang, Y., Zhou, L., Cheng, G., Zhou, Y., Guo, Q., Wu, J., Wong, Y. K., Zhang, J., Tang, H., & Wang, J. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.91 · Cited by 12
Identification of senescent cell subpopulations by CITE ‐seq analysis
Abdelmohsen, K., Mazan-Mamczarz, K., Munk, R. B., Tsitsipatis, D., Meng, Q., Rossi, M. S., Pal, A., Shin, C. H., Martindale, J. L., Piao, Y., et al. (2024) · Aging Cell · doi:10.1111/acel.14297 · Cited by 14
“For example, future studies should study shorter culture times to appreciate the early dynamics of senescence-associated surface proteins, as well as extend the observation periods in cultured cells to examine the long-term effects of senescence (Schafer et al., 2017 ).”
Cellular senescence, p21, and the path to fibrosis
Turano, P. S., & Herbig, U. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00245-8 · Cited by 20
“…that can stimulate a fi brotic phenotype in fi broblasts, it has been suggested that senescent cells promote fi brosis in a non-autonomous manner due to secretion of factors that can damage and alter cells in connective tissue (Hernandez-Gonzalez et al, 2023; Schafer et al, 2017; Wiley et al, 2019).”
InfluentialSpiegel, M. (2025) · Chemistry – A European Journal · doi:10.1002/chem.202403755 · Cited by 12
Zhou, Y., Tong, Z., Zhu, X., Wu, C., Zhou, Y., & Dong, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06031-8 · Cited by 15
“Biomarkers could significantly enhance the diagnostic process, enabling earlier detection and more personalized treatment plans [21, 22].”
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.